Company intelligence / Profile preview
Somite Therapeutics
Boston, Massachusetts, USAsomite.ai ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Somite Therapeutics is leveraging advanced AI models to develop protocols for producing human tissues from stem cells. Their lead programs are in preclinical development, targeting Duchenne muscular dystrophy and metabolic diseases. The company’s proprietary AlphaStem platform enables rapid discovery and optimization of cell differentiation protocols, aiming to accelerate the creation of new cell-based therapies[4][5][6].
- Therapeutic areas
- Metabolic DisordersRheumatologyRare Diseases
- Modalities
- Cell therapy (including cell replacement therapies)Induced pluripotent stem cells (iPSC)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
OmniaBio Inc. (for GMP manufacturing and clinical translation)[5]Astellas Venture Management (investor/board observer)[3]Montage Ventures (investor/board observer)[3]
Beyond the preview
Go deeper on Somite Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Somite Therapeutics.